AM-630
AM-630 is a chemical compound that acts as a selective antagonist for the CB2 receptor, a type of cannabinoid receptor found primarily in the immune system and hematopoietic cells. Unlike the CB1 receptor, which is predominantly located in the central and peripheral nervous system, CB2 receptors are involved in the regulation of immune response and inflammation. AM-630 has been utilized in scientific research to explore the role of CB2 receptors in various physiological and pathological processes.
Chemistry[edit | edit source]
AM-630, chemically known as [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone, is a synthetic compound that belongs to the family of indoles. Its structure allows it to bind selectively to CB2 receptors, inhibiting their activity. This selective antagonism makes AM-630 a valuable tool for studying the function of CB2 receptors without the psychoactive effects associated with CB1 receptor activation, which is typical of many cannabinoids.
Pharmacology[edit | edit source]
The pharmacological significance of AM-630 stems from its ability to modulate the activity of the CB2 receptor. By blocking this receptor, AM-630 can influence various immune and inflammatory responses. Research has shown that CB2 receptors play a crucial role in modulating pain, inflammation, and immune system functions. Therefore, AM-630 and other CB2 receptor antagonists are of interest for developing new treatments for pain, inflammatory diseases, and possibly even some types of cancer.
Research Applications[edit | edit source]
AM-630 is primarily used in preclinical research to understand better the role of CB2 receptors in health and disease. Studies involving AM-630 have contributed to our knowledge of the endocannabinoid system and its involvement in processes such as nociception, immune response, and inflammation. For instance, research using AM-630 has helped elucidate the CB2 receptor's role in modulating pain perception and inflammatory responses in animal models.
Potential Therapeutic Applications[edit | edit source]
While AM-630 itself is mainly a research tool, the insights gained from studies using this compound could lead to the development of new therapeutic agents targeting the CB2 receptor. Such agents could potentially treat a wide range of conditions, including chronic pain, inflammatory and autoimmune diseases, and even certain types of cancer, by modulating the immune system's response.
Safety and Toxicology[edit | edit source]
As with any compound that modulates the immune system, understanding the safety and toxicological profile of AM-630 is crucial. While detailed toxicology studies are necessary to fully assess its safety, research so far suggests that selective CB2 receptor antagonists like AM-630 may have fewer side effects compared to compounds that activate or inhibit CB1 receptors, primarily due to the lack of psychoactive properties.
This article is a stub. You can help WikiMD by registering to expand it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD